Dimethylformamide → N2-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)-N-3-dodecylpyrazine-2,3-dicarboxamide

関与物質

反応手順

Gemcitabine hydrochloride (200 mg, 0.67 mmol), 3-(dodecylcarbamoyl)pyrazine-2-carboxylic acid (325 mg, 1.01 mmol), benzotriazole-1-yl-oxytripyrrolidinylphosphonium hexafluorophosphate (327.6 mg, 0.74 mmol), and 4-dimethylaminopyridine (98 mg, 0.80 mmol) were dissolved in N,N-Dimethylformamide (10 mL) and stirred at room temperature overnight. The reaction mixture was poured into the water, then extracted three times with ethyl acetate. The isolated organic phase was dried with anhydrous Na2SO4. The solvent was removed by vaporizing under reduced pressure. The residue was purified by silica column chromatography (developing agent: dichloromethane/methanol=10/1) to produce 290 mg of N2-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)-N-3-dodecylpyrazine-2,3-dicarboxamide (compound No. 37). LC purity 98% (UV 254). LC-MS m/z 581 [M+H]+, (molecular formula: C27H38F2N6O6, molecular weight: 580). The structure and characterization data of the compound were shown in Table 1.

情報源と証拠